Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug.
about
Nanodiamonds: The intersection of nanotechnology, drug development, and personalized medicineCancer nanomedicine: from targeted delivery to combination therapyTargeting cancer cells in the tumor microenvironment: opportunities and challenges in combinatorial nanomedicine.Ancient genes establish stress-induced mutation as a hallmark of cancerA DNA dual lock-and-key strategy for cell-subtype-specific siRNA delivery.Surface De-PEGylation Controls Nanoparticle-Mediated siRNA Delivery In Vitro and In Vivo.Pt(IV) prodrugs designed to bind non-covalently to human serum albumin for drug deliveryCisplatin modulates B-cell translocation gene 2 to attenuate cell proliferation of prostate carcinoma cells in both p53-dependent and p53-independent pathways.Progress in aptamer-mediated drug delivery vehicles for cancer targeting and its implications in addressing chemotherapeutic challenges.Nanomedicine in the Management of Microbial Infection - Overview and PerspectivesNanodiamond-mitoxantrone complexes enhance drug retention in chemoresistant breast cancer cellsCancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology.Nanoparticles with Precise Ratiometric Co-Loading and Co-Delivery of Gemcitabine Monophosphate and Cisplatin for Treatment of Bladder Cancer.Self-assembled nanoscale coordination polymers carrying siRNAs and cisplatin for effective treatment of resistant ovarian cancer.REV7 is essential for DNA damage tolerance via two REV3L binding sites in mammalian DNA polymerase ζStarvation promotes REV1 SUMOylation and p53-dependent sensitization of melanoma and breast cancer cells.Crosstalk between translesion synthesis, Fanconi anemia network, and homologous recombination repair pathways in interstrand DNA crosslink repair and development of chemoresistanceLong-circulating siRNA nanoparticles for validating Prohibitin1-targeted non-small cell lung cancer treatment.Cooperative Treatment of Metastatic Breast Cancer Using Host-Guest Nanoplatform Coloaded with Docetaxel and siRNA.The Polymerase Activity of Mammalian DNA Pol ζ Is Specifically Required for Cell and Embryonic Viability.Triple-Layered pH-Responsive Micelleplexes Loaded with siRNA and Cisplatin Prodrug for NF-Kappa B Targeted Treatment of Metastatic Breast Cancer.Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug.Nanodrug Formed by Coassembly of Dual Anticancer Drugs to Inhibit Cancer Cell Drug Resistance.Recent advances of cocktail chemotherapy by combination drug delivery systems.Combination Therapy for Ulcerative Colitis: Orally Targeted Nanoparticles Prevent Mucosal Damage and Relieve Inflammation.The influence of p53 mutation status on the anti-cancer effect of cisplatin in oral squamous cell carcinoma cell linesBreakthrough for a DNA break-preventer.Profile of Graham C. Walker.Nanotechnology in the management of cervical cancer.Polymeric 3D nano-architectures for transport and delivery of therapeutically relevant biomacromolecules.Nanocarriers for delivery of siRNA and co-delivery of siRNA and other therapeutic agents.Polymeric biomaterials for the delivery of platinum-based anticancer drugs.CCR 20th Anniversary Commentary: Prospects and Challenges of Therapeutic Nanoparticles in Cancer.Current views on inducing synthetic lethal RNAi responses in the treatment of cancer.Identification of Small Molecule Translesion Synthesis Inhibitors That Target the Rev1-CT/RIR Protein-Protein Interaction.Recent updates in utilizing prodrugs in drug delivery (2013-2015).A Multi-Mitochondrial Anticancer Agent that Selectively Kills Cancer Cells and Overcomes Drug Resistance.Nanoparticle formulations of cisplatin for cancer therapy.Prodrug-based nano-drug delivery system for co-encapsulate paclitaxel and carboplatin for lung cancer treatment.Nanocarrier-based co-delivery of small molecules and siRNA/miRNA for treatment of cancer.
P2860
Q26776095-347AA698-DA05-4FE0-975F-AB6603C311C4Q28083065-923B5174-388B-415E-ACEB-0F659BF03485Q30279055-481C6313-A50E-4C22-8ECE-4DFE85D8690EQ33602374-7C2C4421-240D-498D-89D3-4FCEC6C72183Q33813408-407B247A-5062-4ED8-B193-75B07B6C284BQ33821050-F6C3B852-E462-4AFB-BBD0-9466E7A14712Q33825880-9DECCBF2-E3B2-404A-9BEA-C2911260462CQ33827212-152B3A68-D810-4F35-9912-D25CA865FFB3Q33935498-F0539B43-66B8-4E5A-84F5-B3E84B32599FQ34245494-047CC3D1-1001-4DA7-AFBE-3FE8BA504638Q34435737-C7C4324D-8C2B-43CE-B478-A6264BED4266Q34447986-B99F6CF7-604D-4B59-BBAC-67CACE676788Q34479313-0E3042B5-9046-4EE5-9256-B38D4ED07C39Q34617008-06595544-F79A-4592-A6E9-07A3344D4666Q35098093-60E015C7-D8AD-407C-A1A4-BCAABB724467Q35178418-FCF1A54B-2D84-4DD9-B5A5-36633F524455Q35205030-F3AD42A7-0774-4122-A741-77F944978543Q35796255-B9CA7EAD-7A24-4D6C-9E77-2082211DC68CQ35867861-DB04F611-0D09-4240-ADC7-8445F7DC9F03Q35884176-B2CF6F57-908C-4B0C-9E71-F36DC6E427CAQ36372323-B0020A33-F01D-42E1-B688-6A5E2224DEB6Q36459188-0CABC7A3-FC6A-47A2-8C82-9622B04C3DF6Q36461811-0CE93DD2-9419-4951-BB7A-C9A2A01D1E23Q37206908-6C810607-2014-42B9-90B0-6185DA8F6B95Q37469872-030FA1E7-B155-455C-8713-1AB8AFD2A0E1Q37549047-5835A401-8D15-4E28-8F4A-B38D8B8656D8Q37612668-5462FE05-EBB2-47AA-A7C1-E2DA3EA86573Q37628038-46B1DF51-918A-4E19-9C0A-CAA561170367Q38370785-F75F3FED-1CE7-4C3E-B196-66799F2FF7CBQ38555019-0CF321E6-C909-4C1F-B461-07D9B7DE2F28Q38555082-A486368E-40CF-4C32-939C-ADF2A8905670Q38556758-999DFBBE-FACF-4D56-9465-6487BF58019DQ38608825-8058B2D6-6975-4D77-8F43-7252C2475EBAQ38656763-7DA61E23-C6EE-464E-B0FD-95B76D8763B7Q38679334-41BDE2C1-90C3-435D-A17F-159637FC6168Q38702949-668E6927-80BA-4E28-82A0-E144CDD9DB5CQ38720819-218B4D73-6D81-4BA5-9EB6-080A693BF68DQ38723829-960CC333-0DF8-49E8-9105-9B6340A1441EQ38741016-52F4AA2E-223E-411E-99DA-87C16D12DECFQ38787321-C5A70B56-18EC-402D-BFAF-7017527BA038
P2860
Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Enhancing tumor cell response ...... f siRNA and cisplatin prodrug.
@en
Enhancing tumor cell response ...... f siRNA and cisplatin prodrug.
@nl
type
label
Enhancing tumor cell response ...... f siRNA and cisplatin prodrug.
@en
Enhancing tumor cell response ...... f siRNA and cisplatin prodrug.
@nl
prefLabel
Enhancing tumor cell response ...... f siRNA and cisplatin prodrug.
@en
Enhancing tumor cell response ...... f siRNA and cisplatin prodrug.
@nl
P2093
P2860
P50
P356
P1476
Enhancing tumor cell response ...... of siRNA and cisplatin prodrug
@en
P2093
Danica S Cui
Eric M Pridgen
Ga Young Park
Jinjun Shi
Robert Langer
Stephen J Lippard
Xiaoyang Xu
Xue-Qing Zhang
P2860
P304
18638-18643
P356
10.1073/PNAS.1303958110
P407
P577
2013-10-28T00:00:00Z